Christine Chomienne

Christine Chomienne

Auto-generated profile, based on publicly available information

Christine Chomienne

UMR-S1131, Hôpital Saint Louis, Paris, France

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 1991 in Cell
Verified
Journal Article
Closed access
HTHugues de Thé
Hugues de Thé
CLCatherine Lavau
Catherine Lavau
AMAgnès Marchio
Agnès Marchio
CCChristine Chomienne
Christine Chomienne
LDLaurent Degos
Laurent Degos
ADAnne Dejean
Anne Dejean

1 October 1990 in Nature
Verified
Journal Article
Closed access
HTHugues de Thé
Hugues de Thé
CCChristine Chomienne
Christine Chomienne
MLMichel Lanotte
Michel Lanotte
LDLaurent Degos
Laurent Degos
ADAnne Dejean
Anne Dejean

11 October 2012 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
Peter ValentPeter Valent
Peter Valent
DBDominique Bonnet
Dominique Bonnet
RMRuggero De Maria
Ruggero De Maria
TLTsvee Lapidot
Tsvee Lapidot
MCMhairi Copland
Mhairi Copland
CEConnie Eaves
Connie Eaves

15 October 2008 in Blood
Verified
Journal Article
Closed access
PDF file
JKJean-Jacques Kiladjian
Jean-Jacques Kiladjian
BCBruno Cassinat
Bruno Cassinat
SCSylvie Chevret
Sylvie Chevret
PTPascal Turlure
Pascal Turlure
NCNathalie Cambier
Nathalie Cambier
PFPierre Fenaux
Pierre Fenaux
Interferon-α (IFN-α) is a nonleukemogenic treatment of polycythemia vera (PV) able to induce cytogenetic remissions. Its use is limited by toxicity, leading to treatment discontinuation in approximately 20% of patients. We completed a phase 2 multicenter study of pegylated IFN-α-2a in 40 PV patients. Objectives included evaluation of efficacy, safety, and monitoring of residual disease using JAK2V617F quantification (%V617F). Median follow-up was 31.4 months. At 12 months, all 37 evaluable patients had hematologic response, including 94.6% complete responses (CRs). Only 3 patients (8%) had stopped treatment. After the first year, 35 patients remained in hematologic CR, including 5 who had stopped pegylated IFN-α-2a. Sequential samples for %V617F monitoring, available in 29 patients, showed %V617F decrease in 26 (89.6%). Median %V617F decreased from 45% before pegylated IFN-α-2a to 22.5%, 17.5%, 5%, and 3% after 12, 18, 24, and 36 months, respectively. Molecular CR (JAK2V617F undetectable) was achieved in 7 patients, lasting from 6+ to 18+ months, and persisted after pegylated IFN-α-2a discontinuation in 5. No vascular event was recorded. These results show that pegylated IFN-α-2a yields high rates of hematologic and molecular response in PV with limited toxicity, and could even eliminate the JAK2 mutated clone in selected cases. Available at www.clinicaltrials.gov as #NCT00241241.

6 April 2004 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
CBChristine Bellanné-Chantelot
Christine Bellanné-Chantelot
DCDominique Chauveau
Dominique Chauveau
JGJean-François Gautier
Jean-François Gautier
DDDanièle Dubois-Laforgue
Danièle Dubois-Laforgue
SCSéverine Clauin
Séverine Clauin
JTJosé Timsit
José Timsit
Maturity-onset diabetes of the young type 5 (MODY5), a type of dominantly inherited diabetes mellitus and nephropathy, has been associated with mutations of the hepatocyte nuclear factor-1beta (HNF-1beta) gene, mostly generating truncated protein. Various phenotypes, including urogenital malformations, are related to HNF-1beta mutations. To describe clinical and genetic findings in 13 patients with 8 novel HNF-1beta mutations. Multicenter, descriptive study. 2 departments of diabetes, 1 department of internal medicine, and 1 department of nephrology. 8 probands with diabetes diagnosed before 40 years of age and nondiabetic kidney disease who were selected independent of their family history of diabetes, and 5 offspring. Characteristics of diabetes, renal function and structure, genital tract abnormalities, pancreas structure, insulin secretion, exocrine pancreas function, and liver test results. All mutations, including 5 missense changes, were found in the DNA-binding domain. Cosegregation of the mutation and MODY5 phenotype was observed in 4 families. Occurrence of a de novo mutation was demonstrated in 2 families. Diabetes was present in 10 of 13 mutation carriers. It was clinically overt in 5 participants and found by screening at age 19 to 38 years in 5 participants. Pancreas atrophy was observed in 5 of 6 probands, and pancreas exocrine insufficiency was observed in 6 of 7 probands. Renal involvement, consisting of structural changes and slowly progressive renal failure, was recognized in 9 patients at 18 to 41 years of age. Dysplastic kidneys were found by ultrasonography in 3 fetuses who subsequently showed transient neonatal renal failure. Genital tract abnormalities were present in 5 probands and liver enzyme levels were abnormal in 11 of 13 patients. Since the study was small and not population-based, it could not estimate the prevalence of MODY5. Other phenotypes might be associated with HNF-1beta mutations. Maturity-onset diabetes of the young type 5 encompasses a wide clinical spectrum. Analysis for mutations of HNF-1beta is warranted, even without a family history of diabetes, in nonobese patients with diabetes and slowly progressive nondiabetic nephropathy, particularly when pancreatic atrophy or genital abnormalities are present.

1 June 2001 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
Lucia AltucciLucia Altucci
Lucia Altucci
ARAurelie Rossin
Aurelie Rossin
WRWolfgang Raffelsberger
Wolfgang Raffelsberger
ARArmin Reitmair
Armin Reitmair
CCChristine Chomienne
Christine Chomienne
HGHinrich Gronemeyer
Hinrich Gronemeyer